SCHEDULE: L1 Capital Discloses 9.99% Stake in Dare Biosciences

L1 Capital Global Opportunities Master Fund, Ltd. has reported beneficial ownership of 9.99% of Dare Biosciences, Inc. common stock and warrants.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, reporting beneficial ownership of 2,028,885 shares of Dare Biosciences, Inc. common stock and Series A warrants.
• This ownership stake represents 9.99% of the class of securities.
• The filing specifies that the reported amount includes 1,094,890 shares of Common Stock and 933,995 Series A Warrants, subject to a 9.99% beneficial ownership limitation.
• The filing also notes that the amounts do not include 160,895 Series A Warrants and 1,094,890 Series B Warrants, which are also subject to a 9.99% beneficial ownership limitation.
• The percentage of class is based on 19,375,189 shares of Common Stock outstanding as of August 17, 2026.
• David Feldman and Joel Arber, Directors of L1 Capital Global Opportunities Master Fund, Ltd., may be deemed to beneficially own these securities, but disclaim beneficial ownership for all other purposes.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but not controlling stake acquisition by an institutional investor, with no immediate negative indicators.

Positives

• Institutional investor L1 Capital Global Opportunities Master Fund, Ltd. has taken a significant stake (9.99%) in Dare Biosciences, Inc., which can signal confidence in the company's prospects.
• The filing indicates a substantial holding of both common stock and warrants, suggesting a potentially long-term investment perspective.

Negatives

• The filing does not contain any explicit negative financial or operational information about Dare Biosciences, Inc.

Risks

• The beneficial ownership is subject to a 9.99% limitation, implying potential adjustments or restrictions on further acquisition.
• The inclusion of warrants suggests potential future dilution if exercised, although this is standard for warrant structures.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from Dare Biosciences, Inc. The future outlook for Dare Biosciences would be inferred from their own subsequent filings.

Management Comments

• David Feldman, Director of L1 Capital Global Opportunities Master Fund, Ltd., certified that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by an institutional investor like L1 Capital in a biotechnology company like Dare Biosciences is common. Such filings often precede or follow other corporate actions or strategic shifts within the company or the broader biotech sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this represents a passive investment by L1 Capital, which is a common approach for institutional investors seeking exposure to growth sectors like biotechnology without aiming for control.
• The 9.99% ownership threshold is a standard reporting requirement for institutional investors to avoid triggering stricter Schedule 13D filing obligations, which are typically associated with active control intentions.

Stakeholder Impact

• Shareholders: The acquisition of a significant stake by an institutional investor may be viewed positively, potentially increasing investor confidence and market interest in the stock.
• Management of Dare Biosciences: May need to consider the perspective of L1 Capital in future strategic decisions, although L1 Capital's filing indicates a passive investment.

Next Steps

• L1 Capital Global Opportunities Master Fund, Ltd. will continue to hold its position in Dare Biosciences, Inc., subject to the 9.99% beneficial ownership limitation.
• Dare Biosciences, Inc. may continue its operations and strategic initiatives, with the impact of L1 Capital's investment to be observed in future performance and disclosures.

Key Dates

Recommendation

The filing indicates a significant passive investment by an institutional investor, which is a neutral to slightly positive development. However, without further operational or financial updates from Dare Biosciences, a 'hold' recommendation is appropriate, suggesting investors monitor future company performance and disclosures.

Keywords

Dare Biosciences, L1 Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Warrants, Securities